Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $390 from $383 and keeps an Overweight rating on the shares. Brukinsa came in above Street expectations with the bottom end of total revenue guidance raised to $5.1B-$5.3B, the analyst tells investors in a research note. The firm added that BeOne provided updates across its pipeline, with updated data expected at ASH in December.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $396 from $348 at Citizens JMP
- BeOne Medicines Reports Strong Q3 2025 Growth
- BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating
- BeiGene’s Earnings Call: Record Growth and Positive Outlook
- BeOne Medicines reports Q3 non-GAAP EPS $2.65, consensus 86c